Table 1 Baseline characteristics of study patients
Variables | All (n = 268) | Non-sarcopenia ( n = 131) | Sarcopenia ( n = 137) | P |
|---|---|---|---|---|
Age, y | 72 ± 5 | 71 ± 4 | 72 ± 5 | 0.139 |
Male, n (%) | 118(44.0) | 67(51.1) | 51(37.2) | 0.022 |
BMI (kg/m 2) | 23.6 ± 3.8 | 24.1 ± 3.8 | 23.1 ± 3.6 | 0.024 |
Concomitant diseases, n (%) | ||||
 Diabetes | 30(11.2) | 15(11.5) | 15(10.9) | 0.741 |
 Hypertension | 133(49.6) | 75(57.3) | 58(42.3) | 0.015 |
 COPD | 3(1.1) | 1(0.8) | 2(1.5) | 0.584 |
 Cerebrovascular disease | 23(8.6) | 10(7.6) | 13(9.5) | 0.588 |
NYHA ≧ 3, n (%) | 120(44.8) | 60(45.8) | 60(43.8) | 0.741 |
CONUT ≧ 2, n (%) | 171(63.8) | 82(62.6) | 89(65.0) | 0.687 |
Preoperative laboratory tests | ||||
 Albumin, g/dL | 38.4 ± 2.8 | 38.8 ± 2.2 | 38.0 ± 3.1 | 0.075 |
 Triglyceride, mmol/L | 1.2 ± 1.0 | 1.2 ± 1.0 | 1.2 ± 0.7 | 0.433 |
 Total cholesterol, mmol/L | 4.0 ± 1.0 | 4.0 ± 1.0 | 4.1 ± 1.0 | 0.629 |
 LDL-C, mmol/L | 2.3 ± 1.0 | 2.2 ± 0.8 | 2.3 ± 0.8 | 0.223 |
 HDL-C, mmol/L | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.3 | 0.383 |
 Creatinine, mg/dL | 69.4 ± 22.4 | 69.1 ± 18.0 | 70.0 ± 26.1 | 0.830 |
 eGFR, mL/min/1.73 m2 | 93.8 ± 25.5 | 93.4 ± 22.7 | 94.1 ± 28.0 | 0.822 |
 Hemoglobin, g/L | 127.5 ± 17.8 | 129.3 ± 17.7 | 125.9 ± 17.7 | 0.118 |
 WBC, ×10 9/L | 1.2 ± 1.0 | 6.3 ± 2.8 | 6.7 ± 3.2 | 0.663 |
 Lymphocytes, ×109/L | 2.3 ± 1.0 | 1.6 ± 0.5 | 1.6 ± 0.6 | 0.674 |
Type of surgery, n (%) | ||||
 Valve | 152(56.7) | 72(55.0) | 80(58.4) | |
 Valve + aorta | 45(16.8) | 24(18.3) | 21(15.3) | |
 Valve + Other | 71(26.5) | 35(26.7) | 36(26.3) | 0.897 |
Intraoperative | ||||
 Surgical time, min | 267 ± 80 | 261 ± 75 | 277 ± 85 | 0.109 |
 CPB time, min | 139 ± 51 | 133 ± 43 | 149 ± 58 | 0.025 |
 Aortic cross-clamp time, min | 102 ± 42 | 98 ± 37 | 111 ± 48 | 0.032 |
Computed tomography measurements | ||||
 ESMCSA, cm2 | 28.4 ± 6.8 | 33.5 ± 4.9 | 23.5 ± 4.4 | < 0.001 |
 ESMCT, HU | 33.0 ± 8.9 | 35.8 ± 7.3 | 30.2 ± 9.4 | < 0.001 |
 ESMCSA/BSA, (cm2 /m2 ) | 17.2 ± 3.5 | 20.2 ± 2.1 | 14.5 ± 2.1 | < 0.001 |